Top Cited CPT Papers
2011 Year-to-date
| Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo-Controlled, Crossover Comparison Studies |
D J Angiolillo |
Article |
89.1 |
| The Emerging Role of Electronic Medical Records in Pharmacogenomics |
R A Wilke |
State of the Art |
89.3 |
| Clinical Pharmacogenetics Implementation Consortium Guildelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing |
M V Relling |
Article |
89.3 |
| CPIC: Clinical Pharmacogenetics Implemenation Consortium of the Pharmacogenomics Research Network |
M V Relling |
Practice |
89.3 |
| Pharmaceutical Innovation in the 21st Century: New Drug Approvals in the First Decade, 2000-2009 |
K I Kaitin |
State of the Art |
89.2 |
| The Use of Induced Pluripotent Stem Cells in Drug Development |
I Inoue |
State of the Art |
89.5 |
| Common Nonsynonymous Substitutions in SLCO1B1 Predipose to Statin Intolerance in Routinely Treated Individuals with Type 2 Diabetes: A Go-DARTS Study |
L A Donnelly |
Article |
89.2 |
| Estrogen Receptors: Therapies Targeted to Receptor Subtypes |
S Nilsson |
State of the Art |
89.1 |
| Refining the Benefit-Risk Framework for the Assessment of Medicines: Valuing and Weighting Benefit and Risk Parameters |
S Walker |
Conference Proceedings |
89.2 |
2010
| Obesity, Inflammation, and Cardiovascular Risk |
P Mathieu
|
State of the Art |
87.4 |
Genetic Factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) Are
Predictor Variables for Warfarin Response in Very Elderly, Frail
Inpatients |
E Pautas
|
Article |
87.1 |
Precompetitive Research: A New Prescription for Drug
Development? |
J Woodcock
|
Macroscopy |
87.5 |
Cancer and Inflammation: Implications for Pharmacology and
Therapeutics
|
F Balkwill
|
State of the Art |
87.4 |
Deconstructing the Drug Development Process: The New Face of
Innovation |
K Kaitin
|
Development |
87.3 |
Optimization of Initial Tacrolimus Dose Using Pharmacogenetic
Testing |
E Thervet
|
Article |
87.6 |
The Critical Path Institute's Approach to Precompetitive Sharing
and Advancing Regulatory Science |
R Woosley
|
Commentary |
87.5 |
Transporter Pharmacogenetics and Statin Toxicity
|
M Niemi
|
Practice |
87.1 |
2009
Pharmacogenetics of neonatal opioid toxicity following
maternal use of codeine during breastfeeding: a case-control study |
P Madadi |
Article |
85.1 |
| Risk of myocardial infarction and death associated with the nonsteroidal anti-inflammatory drugs (NSAIDs) among health individuals: a nationwide cohort study |
EL Fosbøl |
Article |
85.2 |
| Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia |
G Stocco |
Article |
85.2 |
| Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus |
B Komoroski |
Article |
85.5 |
| Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure |
AA Mathias |
Article |
85.1 |
| Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects |
B Komoroski |
Article |
85.5 |
| Pharmacoepigenetics: its role in interindividual differences in drug response |
A Gomez |
Discovery |
85.4 |
Safety assessment and dose selection for first-in-human clinical trials
with immunomodulatory monoclonal antibodies |
PY Muller |
State of the Art |
85.3 |
2008
| Influence of CYP2C9 and VKORc1 1173C/T on the risk of hemorrhagic complications in African-American and European-American patients on warfarin |
N Limdi |
Article |
83.2 |
| CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study |
Y Caraco |
Article |
83.3 |
| Cathepsin K inhibitors: a novel target for osteoporsis therapy |
SA Stoch |
Development |
83.1 |
Read these papers now>>
|